세계의 신생아 스크리닝 시장 규모는 2023년에 12억 5,000만 달러로 평가되며, 2024년 13억 4,000만 달러에서 2031년에는 21억 2,000만 달러로 성장하며, 예측 기간(2024-2031년)의 CAGR은 6.8%로 성장할 전망입니다.
출산율 증가, 영유아의 선천성 질환 증가, 소비자의 인식 개선, 정부의 지원책 등이 맞물려 신생아 검진 분야는 강력한 성장 궤도를 그리고 있습니다. 세계보건기구(WHO)는 선천성 질환이 생후 28일 이내 신생아 사망의 원인으로 연간 약 24만 명, 생후 1개월에서 5세까지의 소아 사망이 약 17만 명에 달한다고 지적하며 사태의 심각성을 강조하고 있습니다. 특히 인도의 선천성 대사이상 유병률은 2%에서 7.8%이며, 선천성 갑상선기능저하증은 신생아 1,000명 중 2.1명이 앓고 있으며, 검사가 대중화될수록 큰 시장 잠재력을 가지고 있음을 보여줍니다. 스크리닝 기술의 발전으로 보다 효율적이고 효과적인 검사가 가능해짐에 따라 시장 성장이 더욱 가속화되고 있습니다. 또한 매니토바 주정부가 2022년 6월에 시작한 척수성 근위축증을 포함한 신생아 선별검사를 확대하는 구상과 같은 정부 주도 프로그램은 선별검사 상황을 강화하고 선별검사 프로토콜의 광범위한 채택과 시행을 촉진하는 역할을 할 것입니다. 선천성 질환에 대한 이해도가 높아지고 조기 발견에 대한 사회적 관심이 높아짐에 따라 신생아 선별검사 시장은 2031년까지 상당한 성장을 보일 것으로 예상됩니다. 이러한 요소들이 결합되면 신생아 선별검사에 대한 기술 혁신과 투자에 유리한 환경이 조성되어 의료 분야 이해관계자들이 주목해야 할 중요한 분야로 자리매김할 것입니다.
Global Newborn Screening Market size was valued at USD 1.25 Billion in 2023 and is poised to grow from USD 1.34 Billion in 2024 to USD 2.12 Billion by 2031, growing at a CAGR of 6.8% in the forecast period (2024-2031).
Market insights reveal a robust growth trajectory for the newborn screening sector, driven by a combination of rising birth rates, increasing congenital illnesses among infants, heightened consumer awareness, and supportive government initiatives. The World Health Organization highlights the gravity of the situation, noting that congenital disorders are responsible for approximately 240,000 neonatal deaths annually within the first 28 days of birth, and around 170,000 child deaths from one month to five years old. Specifically, the prevalence of in-born metabolic disorders in India ranges from 2% to 7.8%, with congenital hypothyroidism affecting 2.1 out of every 1,000 newborns, indicating a significant market potential as testing becomes more prevalent. Technological advancements in screening methodologies are further propelling market growth, as more efficient and effective techniques become available. Additionally, government-led programs, such as Manitoba's initiative launched in June 2022 to expand its newborn screening to include spinal muscular atrophy, serve to enhance the screening landscape, encouraging wider adoption and implementation of screening protocols. As the understanding of congenital disorders deepens and societal emphasis on early detection intensifies, the newborn screening market is expected to see considerable expansion through 2031. The convergence of these elements establishes a favorable climate for innovation and investment in newborn screening, positioning it as a critical area of focus for stakeholders in the healthcare sector.
Top-down and bottom-up approaches were used to estimate and validate the size of the Global Newborn Screening market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
Global Newborn Screening Market Segmental Analysis
Global Newborn Screening Market is segmented by Product, Test, technology, end user and region. Based on Product, the market is segmented into Consumables, Instruments, Hearing screening instruments, Pulse oximeters. Based on Test, the market is segmented into Dry blood spot tests, Hearing screening tests, CCHD screening tests. Based on technology, the market is segmented into Immune assays & enzymatic assays, Tandem mass spectrometry, Molecular assays, Hearing screening technologies, Pulse oximetry, Other Technologies. Based on end user, the market is segmented into Clinical Laboratories, Hospitals. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.
Driver of the Global Newborn Screening Market
The rising prevalence of congenital abnormalities is a key market driver for the Global Newborn Screening market, fueling demand for early diagnostic solutions. Conditions such as genetic disorders, hearing impairments, and metabolic disorders emphasize the need for prompt identification and intervention, which can significantly enhance treatment outcomes and the quality of life for affected neonates. As medical technology advances and understanding of the benefits of early diagnosis deepens, the importance of comprehensive screening programs becomes increasingly evident. Additionally, heightened awareness of congenital disorders and focused initiatives to safeguard newborn health are encouraging the adoption of thorough screening techniques, thus bolstering market growth.
Restraints in the Global Newborn Screening Market
The high cost of newborn screening tests presents a significant market restraint, particularly impacting low- and middle-income countries. These financial barriers restrict access to essential screening, preventing families from benefiting from potentially lifesaving treatments. As a result, the delay in detection and intervention can severely compromise the health outcomes of affected neonates. Furthermore, the existing disparity in access to these critical tests highlights the urgent need for more affordable screening options and support networks that promote equitable early diagnostic services. Addressing this monetary limitation is crucial for advancing global infant health and ensuring all newborns receive adequate care.
Market Trends of the Global Newborn Screening Market
The Global Newborn Screening market is witnessing a significant trend towards advanced genetic testing integration, characterized by the adoption of Whole Genome Sequencing (WGS) and Next-Generation Sequencing (NGS). These innovative technologies facilitate the precise identification of a broader range of genetic disorders, including complex and rare conditions often overlooked by traditional methods. As the costs associated with genetic testing continue to decline, the availability of comprehensive screening panels is expanding, enabling earlier and more accurate detection of genetic abnormalities. This evolution not only enhances the efficacy of newborn screening programs but also improves clinical outcomes, driving demand and growth within the market.